Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 3 - Net Loss Per Share of Common Stock

Note 3 - Net Loss Per Share of Common Stock

12 Months Ended

Dec. 31, 2023

3. Net Loss Per Share of Common Stock

Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed, when applicable, using the weighted average number of shares of common stock, adjusted to include conversion of "in-the-money" stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, net of tax as follows:

	*Years ended December 31,*
	*2023*			*2022*
Numerator:

Net loss	$	(15,198	)	$	(15,080	)
Adjustment for gain on fair value of warrant liability		—			—
Adjusted net loss used for dilution calculation	$	(15,198	)	$	(15,080	)

Denominator
Weighted-average number of shares outstanding		13,867			12,962
Effect of potential dilutive shares		—			—
Dilutive weighted-average number of shares outstanding		13,867			12,962

Net loss per share, basic and diluted	$	(1.10	)	$	(1.16	)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	*Years ended December 31,*
	*2023*		*2022*
Options to purchase common stock		252		270
Restricted stock units		1,305		1,383
Warrants for common stock		1,240		1,240
Total common stock equivalents		2,797		2,893